Experimental studies using OMV in a new platform of SARS-CoV-2 vaccines.
Hum Vaccin Immunother
; 17(9): 2965-2968, 2021 09 02.
Article
in English
| MEDLINE | ID: covidwho-1216574
ABSTRACT
Although COVID-19 vaccines have recently been approved for emergency use, search for new vaccines are still urgent, since the access of the countries, especially the poorest, to the vaccines, has shown to be slower than the necessary to rapidly control the pandemic. We proposed a novel platform for vaccine using recombinant receptor binding domain (rRBD) from Sars-Cov-2 spike protein and Neisseria meningitidis outer membrane vesicles (OMVs). The antigen preparation produced a humoral and cellular immune response. Taken together our findings suggest a good immunostimulatory patter in response to immunization with rRBD plus N. meningitidis OMV.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Vaccines
/
Meningococcal Vaccines
/
COVID-19
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Hum Vaccin Immunother
Year:
2021
Document Type:
Article
Affiliation country:
21645515.2021.1920272
Similar
MEDLINE
...
LILACS
LIS